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INTRODUCTION
The cornea maintains its avascularity as a result of a balance bet­
ween angiogenic and anti­angiogenic factors(1,2). It is believed that 
under basal conditions, low levels of angiogenic factors and high 
levels of anti­angiogenic factors maintain the cornea devoid of blood 
and lymphatic vessels(3,4). Disruption of this homeostasis may occur 
in several pathological conditions, including infection, inflammation, 
ischemia, degeneration and trauma, leading to corneal neovascu­
larization (NV) and consequential loss of corneal transparency(1,2). 
Cor neal NV not only reduces visual acuity, but it also causes loss 
of the cornea’s immune privilege, strongly contributing to a worse 
prog no sis in penetrating keratoplasty(2). Preexisting stromal lymph 
and blood vessels are strong risk factors for immune rejection after 
corneal transplantation(5,6).
Several mediators participate in corneal angiogenesis, including 
basic fibroblast growth factor, transforming growth factor, platelet­
de rived growth factor (PDGF) and vascular endothelial growth factor 
(VEGF)(2,4,7). The role of VEGF has been extensively proven, and it is 
often considered the most prominent angiogenic factor(2). VEGF acts 
in the activation, proliferation, migration and differentiation of vas­
cular endothelial cells. It has been shown that VEGF is up regulated 
in vascularized human corneas and that endogenous VEGF­A plays a 
critical role in promoting hemangiogenesis and VEGF­C and VEGF­D 
in lymphangiogenesis under certain pathological conditions(2,8).
Steroids are the main drugs available for inhibiting angiogene­
sis(7). However, their indirect antiangiogenic action is limited, and their 
use is associated with glaucoma and cataract formation(7). 
Anti­VEGF agents have been shown to be effective in slowing 
the growth of corneal neovessels. Pharmacological neutralization of 
VEGF­A completely inhibited both hemangiogenesis and lymphan­
giogenesis in animal models through primary inhibition of blood 
and lymphatic vessel formation(8). Bevacizumab (Avastin; Genen­
tech Inc., San Francisco, California, USA) is a humanized version of a 
monoclonal antibody that binds to all isoforms of VEGF. It has been 
successfully used in ophthalmology in the treatment of age­related 
macular degeneration, proliferative diabetic retinopathy and central 
retinal vein occlusion(9­11). 
Regarding corneal NV, both topical and subconjunctival adminis­
tration of bevacizumab were shown to be effective in diminishing vas ­
cularization(12,13). However, penetration of the drug through an in tact 
epithelium is considered an issue since its molecular weight is high 
(149kDa)(2). For this reason, absorption after topical administration 
may be limited(2). Subconjunctival injections guarantee better delivery, 
although local side­effects have been reported(2). Other di sadvantages 
of these methods are the high cost of topic preparations as well as 
potential systemic side­effects with subconjunctival administration.
Intrastromal corneal injection has been used to treat a case of 
cor neal NV, showing encouraging results(14). A small case series on 
subconjunctival and intracorneal injections of bevacizumab for the 
treatment of lipid keratopathy was also recently published(15). The 
purpose of the present study was to report a series of patients who 
underwent intracorneal bevacizumab injections to treat corneal 
vascularization. 
METHODS
Six eyes (of 6 adult patients, 3 male) with corneal NV secondary 
to various conditions received treatment with intracorneal injection 
of bevacizumab.
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ABSTRACT
Corneal neovascularization (NV) not only reduces visual acuity, but it also causes 
loss of the cornea’s immune privilege, strongly contributing to a worse prognosis 
in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, 
and the role of vascular endothelial growth factor (VEGF) has been extensively 
proven. Anti­VEGF agents have been shown to be effective in slowing the growth 
of corneal neovessels. Bevacizumab, an anti­VEGF agent, has been successfully 
used in the treatment of corneal neovascularization. In this paper, we report a 
series of patients who underwent intracorneal bevacizumab injections to treat 
corneal vascularization.
Keywords: Corneal stroma/drug effects; Corneal neovascularization/drug therapy; 
Injections, intraocular; Antibodies, monoclonal/administration & dosage
RESUMO
Além de causar redução da acuidade visual, a neovascularização corneana leva à 
perda do privilégio imunológico da córnea, contribuindo para um pior prognóstico em 
casos de ceratoplastia penetrante. Diversos mediadores participam da angiogênese 
corneana. O papel do fator de crescimento endothelial vascular (VEGF) já foi ampla-
mente descrito. Agentes inibidores do VEGF são eficazes na redução do crescimento 
de neovasos corneanos. Bevacizumabe, um agente anti-VEGF, tem sido utilizado com 
sucesso no tratamento de neovascularização corneana. Neste artigo, relatamos uma 
série de pacientes que foram submetidos à injeção intraestromal de bevacizumabe 
para o tratamento de vascularização corneana.
Descritores: Substância própria/efeito de drogas; Neovascularização da córnea/qui-
mioterapia; Injeções intraoculares; Anticorpos monoclonais/administração & dosagem
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Ophthalmological examination included BCVA measurement, slit 
lamp biomicroscopy, applanation tonometry, fundus biomicroscopy 
and ocular ultrasonography, when fundoscopy was hampered by 
media opacity.
The injections were performed under a surgical microscope. A 
0.1­mL aliquot of bevacizumab (25 mg/mL) was aseptically prepared 
in an insulin syringe attached to a 31­gauge needle, and intrastro ­
mal injection of approximately 0.01 mL (100 μg) was performed 
after topical anesthesia. Bevacizumab was injected into the corneal 
stroma, next to the neovessels (Figure 1). The exact site of injection 
depended on how far from the limbus or how deep in the cornea the 
vessels were found. The number of injections in each session depen­
ded on the number of quadrants involved. Each case was analyzed 
individually in order to deliver 0.01 mL of bevacizumab to every qua ­
drant containing vessels. Bevacizumab was injected at more than one 
site in the corneal stroma, when more than one quadrant was invol­
ved, in order to cover all areas with NV. When central involvement 
was observed, the needle was introduced in the affected quadrant, 
adjacent to the vessels, but out of the visual axis.
After the injection, the patients were prescribed topical antibio­
tics (moxifloxacin) q.i.d. for 5 days. 
Patients were seen after the injection and on day 1, 7, 15, 21 and 30. 
After day 30, they were seen in clinic according to their pathology’s 
requirement. Photographs on slit­lamp examination were taken 
before and at each post­injection follow­up time. Reduction in the 
extension and caliber of vessels was determined by comparing the 
initial corneal photograph with the subsequent pictures.
The total area of neovascularization was measured dividing each 
corneal quadrant into three sections: peripheral (less than 2 mm 
from the limbus), midperipheral (2­4 mm from the limbus) and 
central (4­6 mm from the limbus). Each corneal quadrant was ana ­
lyzed and given a score: 0 for no vessels, 1 for peripheral, 3 for mid­
pe ripheral, and 5 for central neovascularization. The sum of the four 
quadrants’ values determined the global corneal neovascularization 
score, which was evaluated before and after bevacizumab injection. 
The clinical aspect of the corneal vessels seen on slit­lamp examina­
tion was also considered, and changes in the caliber of neovessels 
after the procedure were recorded.
Exclusion criteria included pregnancy, uncontrolled systemic 
hy pertension and previous history of myocardial infarction and cere­
bral vascular accident. This study was approved by the Institutional 
Review Board of the Federal University of São Paulo, and informed 
consent was obtained from all patients.
RESULTS
The mean age of the 6 patients was 44.67 years (18 and 88 years 
range). The causes of neovascularization included Staphylococcal 
blepharoconjunctivitis in 1 eye (16.67%), herpetic stromal keratitis 
in 2 eyes (33.33%) and failed keratoplasty in 3 eyes (50.00%). The 
cha racteristics of the patients are found in table 1. The mean fol low­
up time was 8.47 months, ranging from 2 to 17 months. The mean 
number of injections per eye was 1.3, ranging from 1 to 2.
Topical anesthesia proved sufficient for pain control, with mini­
mal discomfort during the procedure.
Temporary reduction of visual acuity secondary to transitory cor­
neal edema was reported right after the injection and was no longer 
present on day 1. Intraocular pressure did not change. Intrastromal 
injection did not cause corneal necrosis, chronic epithelial defect or 
any other noticeable local or systemic side­effect. 
At the screening visit, 2 eyes showed neovessels reaching the 
central area of the cornea (more than 4 mm from the limbus), and 
4 had peripheral or mid­peripheral involvement (2 mm and 4­6 mm 
from the limbus, respectively). In one month, 4 (66.67%) of the 6 eyes 
showed a reduction in the total area of neovascularization (patients 
number 1, 2, 4 and 6), and the caliber of neovessels was decreased in 
5 (83.33%) (patients number 1, 2, 3, 4 and 6) (Figure 2). These results 
are shown in table 1.
Regarding the number of injections, patients 1,2, 4 and 5 received 
only 1 injection of bevacizumab, while patients 3 and 6 received 2 
injections each, with a 30­day interval. Patients 1 and 2 each received 
injection once and only in 1 quadrant, since both patients presented 
a single quadrant vascularized and showed visible improvement in 
vascularization. For the same reason, patient number 4 was injected 
only once in each one of the 4 quadrants affected. As already men ­
tioned, patient number 6 required two sessions to show diminish­
ment of vascularization. Patient 3 also received 2 injections, however 
since there was no change in the number of neovessels after the 
second procedure, we opted not to try another attempt. Due to the 
absolute lack of response after the first injection, only one attempt 
was made in patient number 5. In all other cases, at least a small de­
crease in the caliber was observed after injection, which encouraged 
us to believe that there would be a positive response if a second 
attempt were made. In this case (patient 5), there was absolutely no 
change in NV after the first injection.
DISCUSSION
In this study, the injection of bevacizumab into the corneal stro ­
ma was performed in order to treat corneal vessels and no local com­
plications were observed in the follow­up period, which ranged from 
2 to 17 months. Injection of bevacizumab was not painful. Systemic 
side effects were also not found. 
Comparing to other forms of administration, intrastromal injec ­
tion may possibly allow greater exposure of the corneal vessels to the 
drug, as well as delivery of a known concentration of the drug. Topi ­
cal administration of this drug can be affected by limited penetration 
through an intact epithelium due to bevacizumab’s high molecular 
weight(2). Intrastromal administration also guarantees less likelihood 
of treatment failure due to a patient’s lack of compliance. Patients 
may occasionally forget to instill the drug at home, when using a 
topical preparation.
In this study, three patients with post­keratoplasty corneal neo ­
vascularization were treated with intrastromal bevacizumab, 2 pa ­
tients showing reduction of vessels. In these cases of post­kerato­
plasty neovascularization reaching the graft, injecting bevacizumab 
directly into the donor button did not cause corneal necrosis, edema 
or graft rejection. Inhibition of post­operative hemangiogenesis and 
lymphangiogenesis, by neutralization of VEGF­A, increases corneal 
graft survival, even after high­risk transplantation(6). It is possible that Figure 1. Corneal intrastromal bevacizumab injection.
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Table 1. Patients’ profiles and outcomes of intracorneal bevacizumab injections
Age Diagnosis
Site of neovessels
pre-bevacizumab
Score
pre-bevacizumab
Site of neovessels
post-bevacizumab
Score
post-bevacizumab
Reduction of caliber 
post-bevacizumab
1 18 Staphylococcal  
keratoconjunctivitis
Central
1 quadrant
09 ­ 0 Yes
2 30 Post­herpetic  
corneal opacity
Midperipheral
1 quadrant
04 ­ 0 Yes
3 88 Post­herpetic  
corneal opacity
Central
2 quadrants
18 Central
2 quadrants
18 Yes
4 20 Post­keratoplasty Peripheral
4 quadrants
04 Peripheral
1 quadrant
01 Yes
5 33 Post­keratoplasty Peripheral
4 quadrants
04 Peripheral
4 quadrants
04 No
6 79 Post­keratoplasty Peripheral
4 quadrants
04 Peripheral
1 quadrant
01 Yes
other cytokines may have contributed to these results, such as matrix 
metalloproteinases for example, which may be present in the cornea 
after transplantation and have angiogenic and anti­angiogenic actions 
under different conditions(2).
The scoring system used in this paper has not been used in 
pre vious studies. Despite not having the ideal scoring system for 
quantification of corneal neovascularization and documentation of 
changes in vessels’ caliber, our results showed that intracorneal injec­
tion of bevacizumab was safe and effective when used for therapy of 
corneal neovascularization in 6 patients.
Our results suggest that corneal intrastromal injection of beva­
cizumab may be an additional useful option for management of 
corneal vascularization. However, our study has limitations: it was an 
uncontrolled small case series with a short follow­up. The safety of 
intracorneal bevacizumab injections should be further investigated 
in a controlled way and with a larger population. Also, the most 
efficacious administration route has yet to be determined through 
larger trials. 
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Figure 2. A1-A2) Patient 4: Pre-bevacizumab stromal corneal injection, showing pe -
ripheral corneal vessels reaching the graft. B1-B2) Patient 4: Four weeks later, regression 
of NV. C) Patient 3: Pre-bevacizumab injection. New vessels in the central cornea in 
two corneal quadrants. D) Patient 3: Three weeks post-injection. Reduction in vessel 
caliber and number.
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